[HTML][HTML] m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade

S Yang, J Wei, YH Cui, G Park, P Shah, Y Deng… - Nature …, 2019 - nature.com
S Yang, J Wei, YH Cui, G Park, P Shah, Y Deng, AE Aplin, Z Lu, S Hwang, C He, YY He
Nature communications, 2019nature.com
Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-
methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein
(FTO) increases melanoma growth and decreases response to anti-PD-1 blockade
immunotherapy. FTO level is increased in human melanoma and enhances melanoma
tumorigenesis in mice. FTO is induced by metabolic starvation stress through the autophagy
and NF-κB pathway. Knockdown of FTO increases m6A methylation in the critical …
Abstract
Melanoma is one of the most deadly and therapy-resistant cancers. Here we show that N6-methyladenosine (m6A) mRNA demethylation by fat mass and obesity-associated protein (FTO) increases melanoma growth and decreases response to anti-PD-1 blockade immunotherapy. FTO level is increased in human melanoma and enhances melanoma tumorigenesis in mice. FTO is induced by metabolic starvation stress through the autophagy and NF-κB pathway. Knockdown of FTO increases m6A methylation in the critical protumorigenic melanoma cell-intrinsic genes including PD-1 (PDCD1), CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma (IFNγ) and sensitizes melanoma to anti-PD-1 treatment in mice, depending on adaptive immunity. Our findings demonstrate a crucial role of FTO as an m6A demethylase in promoting melanoma tumorigenesis and anti-PD-1 resistance, and suggest that the combination of FTO inhibition with anti-PD-1 blockade may reduce the resistance to immunotherapy in melanoma.
nature.com